Emergent BioSolutions Inc. (EBS) › Shareholders' EquityEmergent BioSolutions Inc. (EBS) — Shareholders' EquityAnnual figures by period end, from SEC filings.2010-12-31: $369.46M2011-12-31: $414.25M2012-12-31: $441.36M2013-12-31: $489.62M2014-12-31: $553.20M2016-12-31: $596.20M2017-12-31: $912.30M2018-12-31: $1.01B2019-12-31: $1.09B2020-12-31: $1.45B2021-12-31: $1.61B2022-12-31: $1.39B2023-12-31: $649.30M2024-12-31: $482.80M2025-12-31: $522.60M$522.60M2010-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31$522.60M+8.2%2026-02-27Balance as of period end2024-12-31$482.80M-25.6%2026-02-27Balance as of period end2023-12-31$649.30M-53.2%2026-02-27Balance as of period end2022-12-31$1.39B-13.9%2026-02-27Balance as of period end2021-12-31$1.61B+11.1%2025-03-04Balance as of period end2020-12-31$1.45B+33.0%2024-03-08Balance as of period end2019-12-31$1.09B+8.0%2023-12-11Balance as of period end2018-12-31$1.01B+10.8%2022-02-25Balance as of period end2017-12-31$912.30M+53.0%2021-02-19Balance as of period end2016-12-31$596.20M—2020-02-25Balance as of period end2014-12-31$553.20M+13.0%2015-03-09Balance as of period end2013-12-31$489.62M+10.9%2015-03-09Balance as of period end2012-12-31$441.36M+6.5%2014-03-10Balance as of period end2011-12-31$414.25M+12.1%2013-03-08Balance as of period end2010-12-31$369.46M—2012-03-09Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)